• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MASLD: a disease in flux.

作者信息

Allen Alina M, Arab Juan Pablo, Wong Vincent Wai-Sun

机构信息

Department of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.

出版信息

Nat Rev Gastroenterol Hepatol. 2024 Nov;21(11):747-750. doi: 10.1038/s41575-024-00990-5. Epub 2024 Oct 2.

DOI:10.1038/s41575-024-00990-5
PMID:39358590
Abstract
摘要

相似文献

1
MASLD: a disease in flux.代谢相关脂肪性肝病：一种不断变化的疾病。
Nat Rev Gastroenterol Hepatol. 2024 Nov;21(11):747-750. doi: 10.1038/s41575-024-00990-5. Epub 2024 Oct 2.
2
Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.细胞核内的miR-204-3p可减轻小鼠代谢功能障碍相关脂肪性肝病。
J Hepatol. 2024 Jun;80(6):834-845. doi: 10.1016/j.jhep.2024.01.029. Epub 2024 Feb 6.
3
Detecting altered hepatic lipid oxidation by MRI in an animal model of MASLD.通过 MASLD 动物模型的 MRI 检测肝脂质氧化改变。
Cell Rep Med. 2024 Sep 17;5(9):101714. doi: 10.1016/j.xcrm.2024.101714. Epub 2024 Sep 5.
4
Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease.代谢功能障碍相关脂肪性肝病与非酒精性脂肪性肝病之间的一致性
Hepatol Res. 2024 Jun;54(6):600-605. doi: 10.1111/hepr.14011. Epub 2024 Jan 17.
5
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review.代谢功能障碍相关脂肪性肝病（MASLD）：最新综述
J Obes Metab Syndr. 2023 Sep 30;32(3):197-213. doi: 10.7570/jomes23052. Epub 2023 Sep 13.
6
Emerging therapies for MASLD and their impact on plasma lipids.非酒精性脂肪性肝炎的新兴疗法及其对血脂的影响。
Am J Prev Cardiol. 2024 Feb 5;17:100638. doi: 10.1016/j.ajpc.2024.100638. eCollection 2024 Mar.
7
Nano-drug delivery systems (NDDS) in metabolic dysfunction-associated steatotic liver disease (MASLD): current status, prospects and challenges.代谢功能障碍相关脂肪性肝病（MASLD）中的纳米药物递送系统（NDDS）：现状、前景与挑战
Front Pharmacol. 2024 Aug 6;15:1419384. doi: 10.3389/fphar.2024.1419384. eCollection 2024.
8
When metabolic comorbidities and risk of malnutrition coexist: The new era of inflammatory bowel disease.当代谢合并症与营养不良风险并存时：炎症性肠病的新时代。
Am J Med Sci. 2025 Jan;369(1):53-61. doi: 10.1016/j.amjms.2024.07.036. Epub 2024 Aug 2.
9
Fatty Liver Disease: Enter the Metabolic Era.脂肪肝疾病：进入代谢时代。
Curr HIV/AIDS Rep. 2023 Dec;20(6):405-418. doi: 10.1007/s11904-023-00669-7. Epub 2023 Oct 26.
10
Metabolic dysfunction-associated steatotic liver disease criteria may underestimate the number of lean female nonalcoholic fatty liver disease patients with significant liver fibrosis.代谢功能障碍相关脂肪性肝病标准可能会低估患有显著肝纤维化的瘦型女性非酒精性脂肪性肝病患者的数量。
Hepatol Res. 2024 May;54(5):429-438. doi: 10.1111/hepr.13994. Epub 2023 Dec 13.

引用本文的文献

1
Hepatic-specific vitamin D receptor downregulation alleviates aging-related metabolic dysfunction-associated steatotic liver disease.肝脏特异性维生素D受体下调可减轻衰老相关代谢功能障碍相关性脂肪性肝病。
World J Gastroenterol. 2025 Apr 14;31(14):104117. doi: 10.3748/wjg.v31.i14.104117.

本文引用的文献

1
Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD.PNPLA3小干扰RNA在I148M纯合子MAFLD患者中的1期试验
N Engl J Med. 2024 Aug 1;391(5):475-476. doi: 10.1056/NEJMc2402341.
2
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.替尔泊肽治疗代谢相关脂肪性肝炎伴肝纤维化
N Engl J Med. 2024 Jul 25;391(4):299-310. doi: 10.1056/NEJMoa2401943. Epub 2024 Jun 8.
3
Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease.
振动控制瞬时弹性成像评分预测脂肪性肝病患者的肝脏相关事件。
JAMA. 2024 Apr 16;331(15):1287-1297. doi: 10.1001/jama.2024.1447.
4
Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis.代谢相关脂肪性肝炎中衰老肝星状细胞的表型和个体发生。
J Hepatol. 2024 Aug;81(2):207-217. doi: 10.1016/j.jhep.2024.03.014. Epub 2024 Mar 18.
5
Implications of the evolving knowledge of the genetic architecture of MASLD.代谢相关脂肪性肝病（MASLD）遗传结构不断演变的知识所带来的影响。
Nat Rev Gastroenterol Hepatol. 2024 Jan;21(1):5-6. doi: 10.1038/s41575-023-00866-0.
6
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease.酒精性肝病与非酒精性脂肪性肝病的交集。
Nat Rev Gastroenterol Hepatol. 2023 Dec;20(12):764-783. doi: 10.1038/s41575-023-00822-y. Epub 2023 Aug 15.
7
Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial.通过自动化纤维化评分计算和电子提醒信息检测 2 型糖尿病患者的晚期肝病的临床护理路径：一项随机对照试验。
Gut. 2023 Nov 24;72(12):2364-2371. doi: 10.1136/gutjnl-2023-330269.
8
Targeting senescent hepatocytes using the thrombomodulin-PAR1 inhibitor vorapaxar ameliorates NAFLD progression.靶向衰老的肝细胞使用血栓调节蛋白-PAR1 抑制剂沃拉帕沙可改善非酒精性脂肪性肝病的进展。
Hepatology. 2023 Oct 1;78(4):1209-1222. doi: 10.1097/HEP.0000000000000401. Epub 2023 Apr 11.
9
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病成人患者结局的前瞻性研究。
N Engl J Med. 2021 Oct 21;385(17):1559-1569. doi: 10.1056/NEJMoa2029349.
10
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病患者风险分层与管理的临床护理路径。
Gastroenterology. 2021 Nov;161(5):1657-1669. doi: 10.1053/j.gastro.2021.07.049. Epub 2021 Sep 20.